These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21791335)

  • 1. Relation of homocysteinemia to contrast-induced nephropathy in patients undergoing percutaneous coronary intervention.
    Kim SJ; Choi D; Ko YG; Kim JS; Han SH; Kim BK; Kang SW; Hong MK; Jang Y; Choi KH; Yoo TH
    Am J Cardiol; 2011 Oct; 108(8):1086-91. PubMed ID: 21791335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.
    Barbieri L; Verdoia M; Schaffer A; Niccoli G; Perrone-Filardi P; Bellomo G; Marino P; Suryapranata H; Luca GD
    Angiology; 2015 Apr; 66(4):333-8. PubMed ID: 24830422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
    Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty.
    Ivanes F; Isorni MA; Halimi JM; Fauchier L; Saint Etienne C; Babuty D; Angoulvant D; Brunet-Bernard A
    Arch Cardiovasc Dis; 2014; 107(8-9):424-32. PubMed ID: 25082735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Value of Gamma-Glutamyl Transferase Levels for Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention.
    Oksuz F; Yarlioglues M; Cay S; Celik IE; Mendi MA; Kurtul A; Cankurt T; Kuyumcu S; Canpolat U; Turak O
    Am J Cardiol; 2015 Sep; 116(5):711-6. PubMed ID: 26116992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment.
    Pyxaras SA; Sinagra G; Mangiacapra F; Perkan A; Di Serafino L; Vitrella G; Rakar S; De Vroey F; Santangelo S; Salvi A; Toth G; Bartunek J; De Bruyne B; Wijns W; Barbato E
    Am J Cardiol; 2013 Mar; 111(5):684-8. PubMed ID: 23261003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Andò G; Morabito G; de Gregorio C; Trio O; Saporito F; Oreto G
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):878-85. PubMed ID: 23703775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
    Bolognese L; Falsini G; Schwenke C; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
    Am J Cardiol; 2012 Jan; 109(1):67-74. PubMed ID: 21943940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention.
    Liu Y; Tan N; Zhou YL; Chen YY; Chen JY; Chen J; Luo JF
    J Nephrol; 2012; 25(3):332-40. PubMed ID: 21928234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ratio of contrast volume to glomerular filtration rate predicts in-hospital and six-month mortality in patients undergoing primary angioplasty for ST-elevation myocardial infarction.
    Çiçek G; Bozbay M; Açıkgöz SK; Altay S; Uğur M; Köroğlu B; Uyarel H
    Cardiol J; 2015; 22(1):101-7. PubMed ID: 24671903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
    Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
    Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of the Logistic Clinical Syntax Score in the Prediction of Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention.
    Ozturk D; Celik O; Erturk M; Kalkan AK; Uzun F; Akturk IF; Akin F; Yildirim A
    Can J Cardiol; 2016 Feb; 32(2):240-6. PubMed ID: 26255218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention.
    Chanin JM; Yang DC; Haider MA; Swaminathan RV; Kim LK; Charitakis K; Tanoue M; Minutello RM; Gade CL; Singh HS; Bergman G; Wong SC; Feldman DN
    J Invasive Cardiol; 2015 Nov; 27(11):490-6. PubMed ID: 25999136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.
    Barbieri L; Verdoia M; Schaffer A; Cassetti E; Marino P; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):181-6. PubMed ID: 25315668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Chronic Total Occlusion Versus Non-Occlusive Coronary Artery Disease.
    Demir OM; Lombardo F; Poletti E; Laricchia A; Beneduce A; Maccagni D; Slavich M; Giannini F; Carlino M; Margonato A; Cappelletti A; Colombo A; Azzalini L
    Am J Cardiol; 2018 Dec; 122(11):1837-1842. PubMed ID: 30292337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of plasma homocysteinemia on contrast-induced nephropathy after percutaneous coronary intervention in patients with coronary syndrome].
    Yan G; Kong W; Wang D; Qiao Y; Sha X; Cheng T; Zhang H; Hou J; Tang C; Ma G
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Jan; 44(1):32-7. PubMed ID: 26813550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention.
    Chong E; Shen L; Poh KK; Tan HC
    Singapore Med J; 2012 Mar; 53(3):164-9. PubMed ID: 22434288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent Renal Dysfunction in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.
    Kurogi K; Ishii M; Sakamoto K; Komaki S; Marume K; Kusaka H; Yamamoto N; Arima Y; Yamamoto E; Kaikita K; Tsujita K
    J Am Heart Assoc; 2019 Dec; 8(23):e014096. PubMed ID: 31766973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience.
    Wang Y; Zhao HW; Zhang XJ; Chen BJ; Yu GN; Hou AJ; Luan B
    BMC Cardiovasc Disord; 2019 Mar; 19(1):74. PubMed ID: 30922230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.